BRAF and melanoma: To test the hypothesis that distinct cellular subpopulations and transcriptional programs underlie clinical differences between BRAF wildtype and V600E variant brain metastases, we performed snRNA-seq on treatment-naive BRAF wildtype (n = 3) and BRAF V600E variant (n = 3) melanoma brain metastases.